Alliancebernstein L.P. Purchases 21,100 Shares of Dynavax Technologies Corporation (DVAX)

Alliancebernstein L.P. lifted its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 46.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,720 shares of the biopharmaceutical company’s stock after purchasing an additional 21,100 shares during the quarter. Alliancebernstein L.P. owned 0.13% of Dynavax Technologies Corporation worth $644,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bank of America Corp DE raised its stake in shares of Dynavax Technologies Corporation by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 456 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 939 shares in the last quarter. American International Group Inc. raised its stake in shares of Dynavax Technologies Corporation by 7.1% in the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 1,584 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Dynavax Technologies Corporation by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,700 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Dynavax Technologies Corporation by 18.5% in the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 1,950 shares in the last quarter. Institutional investors and hedge funds own 59.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2017/11/02/alliancebernstein-l-p-purchases-21100-shares-of-dynavax-technologies-corporation-dvax.html.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same period in the previous year, the firm earned ($0.75) EPS.

DVAX has been the subject of a number of recent research reports. William Blair restated an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated an “outperform” rating and set a $28.00 price objective (up from $26.00) on shares of Dynavax Technologies Corporation in a research note on Monday, September 25th. Zacks Investment Research upgraded Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. J P Morgan Chase & Co upgraded Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $6.00 to $27.00 in a research note on Monday, July 31st. Finally, BidaskClub lowered Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Dynavax Technologies Corporation currently has an average rating of “Buy” and a consensus price target of $25.00.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply